BridgeBio Pharma Inc vs Moderna, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Moderna, Inc. trades at $60.83 (market cap $23.88B). The key difference: Moderna, Inc. is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | MRNA | |
|---|---|---|
Market Cap | $16.61B | $23.88B |
Sector | Health | Health |
52-Week High | $90.17 | $81.80 |
52-Week Low | $47.29 | $22.36 |
Enterprise Value | $18.16B | $20.03B |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →